CV vs POSC vs PHG Stock Comparison

CapsoVision, Positron and Koninklijke Philips Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (BFLY) Create a free account to keep reading and compare up to 10 companies.
CV CapsoVision, Inc
$7.06 +2.0% 1M +50.5% 1Y
Market cap
$347.57M
P/E
–
Revenue (TTM)
$14.41M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
POSC Positron Corp
$1.72 -7.0% 1M +14.7% 1Y
Market cap
$55.84M
P/E
–
Revenue (TTM)
$462.27K
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
PHG Koninklijke Philips Nv
$27.05 +7.7% 1M -0.9% 1Y
Market cap
$25.74B
P/E
14.0x
Revenue (TTM)
$20.60B
Div. yield
–
Diagnostic Equipment Healthcare
4 wins

Head to Head

8 decided of 12

Koninklijke Philips leads on 4 of the 12 questions below (Koninklijke Philips 4, Positron 3, CapsoVision 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVPOSCPHGLeader
Larger companyMarket capitalisation $347.57M $55.84M $25.74B PHG
Cheaper on earningsLower P/E, profitable companies only -12.7x -11.4x 14.0x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 13.7x –
Faster revenue growthRevenue growth, trailing twelve months +14.6% +202.2% +6.1% POSC
More profitableNet margin, trailing twelve months -190.2% -1,060.5% 8.9% PHG
Better return on capitalReturn on invested capital — — 11.5% –
Less leveragedLower net debt / EBITDA — -0.3x 1.8x POSC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +50.5% +14.7% -0.9% CV
Better 5-year returnAnnualised price return, 5 years — +23.5%/yr -10.6%/yr POSC
Less volatileAnnualised volatility, 1 year 96.0% 86.7% 28.3% PHG
Higher overall scoreMean of the five percentile scores vs peers 37/100 13/100 80/100 PHG

Percentile Scorecard

CVPOSCPHG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVPOSCPHG
Valuation 6 #214 of 227 21 #179 of 227 98 #6 of 227
Growth 44 #124 of 219 19 #177 of 219 95 #11 of 219
Profitability 23 #158 of 205 4 #197 of 205 96 #9 of 205
Financial Health 75 #59 of 237 4 #227 of 237 31 #163 of 237
Shareholder Returns – 19 #110 of 135 79 #29 of 135
Overall 37 13 80
  • CV ranked among 247 companies in Medical Devices and Diagnostics
  • POSC ranked among 247 companies in Medical Devices and Diagnostics
  • PHG ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVPOSCPHGSPY
1 month +2.0%-7.0%+7.7% +0.9%
3 months +6.5%+7.5%+3.6% +5.9%
6 months +10.3%-7.0%+5.7% +8.5%
Year to date -34.0%+3.0%-0.1% +13.3%
1 year +50.5%+14.7%-0.9% +12.4%
3 years —+37.6%+46.2% +88.1%
3 years, per year —+11.2%+13.5% +23.5%
5 years —+186.7%-42.8% +68.2%
5 years, per year —+23.5%-10.6% +11.0%
10 years —+5,633.3%-10.4% +263.4%
10 years, per year —+49.9%-1.1% +13.8%

Risk

MeasureCVPOSCPHGSPY
Volatility, 1Y 96.0%86.7%28.3% 12.7%
Downside volatility, 1Y 89.6%87.5%27.7% 12.7%
Beta vs S&P 500, 1Y 0.620.280.82 1.00
Return / volatility, 1Y 0.530.17-0.03 0.98
Max drawdown, 5Y -67.8%-65.6%-75.6% -25.4%
From 52-week high -51.0%-32.8%-17.8% -0.9%
52-week high $14.42$2.56$32.91 $779.14
52-week low $4.59$1.31$23.81 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVPOSCPHG
P/E now vs peer median -12.9xmedian 28.8x -11.5xmedian 28.8x 13.9xmedian 28.8x
P/S now vs peer median 24.5xmedian 3.0x 122.2xmedian 3.0x 1.3xmedian 3.0x
EV/EBITDA now vs peer median -12.8xmedian 17.4x -12.2xmedian 17.4x 8.2xmedian 17.4x
P/FCF now vs peer median —median 25.7x -13.6xmedian 25.7x 6.0xmedian 25.7x
P/B now vs peer median 26.8xmedian 2.4x -85.5xmedian 2.4x 2.0xmedian 2.4x
PEG now vs peer median —median 1.03 —median 1.03 0.33median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVPOSCPHG
Revenue $14.41M $462.27K $20.60B
Gross profit $7.55M -$1.33M $16.03B
Operating income -$27.71M -$4.82M $2.65B
Net income -$27.42M -$4.90M $1.39B
Free cash flow – -$4.16M $4.34B
R&D $20.51M – $2.00B
EPS (diluted) $-0.55 $-0.15 $1.91
Cash & equivalents – $357.17K $2.04B
Total debt – $2.00M $9.51B
Shares (diluted) 49.94M 32.85M 962.50M
Enterprise value $347.57M $48.56M $14.86B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVPOSCPHG
P/E -12.9x -11.5x 13.9x
P/FCF – -13.6x 6.0x
P/Operating cash flow – -13.6x 9.8x
P/S 24.5x 122.2x 1.3x
P/B 26.8x -85.5x 2.0x
P/Tangible book 26.8x -85.5x 2.6x
EV/EBITDA -12.8x -12.2x 8.2x
EV/EBIT -12.7x -12.1x 12.6x
EV/Revenue 24.5x 125.8x 1.6x
EV/FCF – -14.0x 7.7x
EV/Operating cash flow – -14.0x 12.6x
PEG (3Y EPS CAGR) – – 0.33

Growth

14 metrics
MetricCVPOSCPHG
Revenue growth (1Y) 14.6% 202.2% 6.1%
Revenue CAGR (3Y) – – 2.3%
Gross profit growth (1Y) 11.1% -15.2% 82.4%
Gross profit CAGR (3Y) – – 6.7%
Operating income growth (1Y) -36.1% -17.5% 121.3%
Operating income CAGR (3Y) – – 52.0%
Net income growth (1Y) -34.9% -18.0% 293.5%
Net income CAGR (3Y) – – 35.6%
EPS growth (1Y) 93.8% -12.5% 539.4%
EPS CAGR (3Y) – – 42.2%
Operating cash flow growth (1Y) – -17.0% 116.7%
Operating cash flow CAGR (3Y) – – 53.6%
Free cash flow growth (1Y) – -17.0% 54.2%
Free cash flow CAGR (3Y) – – 45.6%

Profitability

14 metrics
MetricCVPOSCPHG
Gross margin 52.4% -288.1% 77.8%
EBITDA margin -190.7% -1,030% 19.8%
Operating margin -192.3% -1,042% 12.9%
Pretax margin -190.1% -1,060% 11.9%
Net margin -190.2% -1,060% 8.9%
FCF margin – -900.4% 21.1%
Operating cash flow margin – -900.4% 12.9%
Return on equity -207.5% – 12.7%
Return on assets -149.3% -216.9% 5.4%
Return on invested capital – – 11.5%
Return on capital employed -209.8% -61,094% 11.8%
Asset turnover 0.8x 0.2x 0.7x
Cash conversion (OCF / net income) – 0.8x 1.9x
Stock comp / revenue – – 0.7%

Financial Health

11 metrics
MetricCVPOSCPHG
Debt / assets – 115.8% 31.2%
Debt / equity – -3.0x 0.7x
Net debt / EBITDA – -0.3x 1.8x
Debt / FCF – -0.5x 2.2x
Liabilities / assets 29.1% 138.2% 57.1%
Equity / assets 70.9% -38.2% 42.9%
Interest coverage – -43.8x 6.2x
Current ratio 3.4x 0.5x 1.3x
Quick ratio – 0.2x 0.7x
Cash ratio – 0.2x 0.2x
Altman Z-score 23.03 -114.72 –

Shareholder Returns

7 metrics
MetricCVPOSCPHG
Dividend yield – – 3.7%
Net buyback yield – -5.3% -0.5%
Shareholder yield 0.0% -5.3% 3.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVPOSCPHG
Forward P/E – – 13.7xFY2026
EPS, next fiscal year $-0.58FY2026 – $1.98FY2026
EPS growth, next FY – – +6.5%FY2026
EPS growth, the year after – – -10.1%
Revenue, next fiscal year $13.91MFY2026 – $21.63BFY2026
Revenue growth, next FY +2.7%FY2026 – +1.8%FY2026
Revenue growth, the year after +46.0% – -8.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVPOSCPHG
Held by institutions 10.2% – 5.4%
Institutions holding 50 – 363
Change in shares held, QoQ +27.6% – +0.8%
Institutions buying 36 – 266
Institutions selling 8 – 76
Buyers to sellers 4.50 – 3.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVPOSCPHG
CV 1.00 0.01 -0.01
POSC 0.01 1.00 0.02
PHG -0.01 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CV, POSC and PHG?

Koninklijke Philips (PHG) is the largest by market capitalisation: CapsoVision (CV) $347.57M, Positron (POSC) $55.84M, Koninklijke Philips (PHG) $25.74B.

Which company is growing faster?

Positron (POSC) grew revenue fastest over the trailing twelve months: CapsoVision (CV) +14.6%, Positron (POSC) +202.2%, Koninklijke Philips (PHG) +6.1%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (CapsoVision (CV) -190.2%, Positron (POSC) -1,060.5%, Koninklijke Philips (PHG) 8.9%).

Which stock has performed better?

Over the past year CapsoVision (CV) returned the most: CapsoVision (CV) +50.5%, Positron (POSC) +14.7%, Koninklijke Philips (PHG) -0.9%. Over five years, Positron (POSC) compounded fastest (Positron (POSC) +23.5%/yr, Koninklijke Philips (PHG) -10.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (CapsoVision (CV) 96.0%, Positron (POSC) 86.7%, Koninklijke Philips (PHG) 28.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CV, POSC and PHG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.